Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy for recurrent or metastatic cervical carcinoma after failure of standard treatment
ChiCTR1800016846Phase 4Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Cervical Cancer (CC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: progression-free survival. Started Jul 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800016846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016846.